Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Immuneering Corp shares valued at $89,278 were purchased by Schall Thomas J. on Jun 17 ’25. At $2.21 per share, Schall Thomas J. acquired 40,485 shares. The insider’s holdings grew to 43,385 shares worth approximately $0.12 million following the completion of this transaction.
As published in a research note from Morgan Stanley on December 13, 2024, Immuneering Corp [IMRX] has been rated down from an Equal-weight to an Underweight. Analysts at Needham resumed the stock at ‘”a Buy”‘ outlook in a report released in mid March. As of March 15, 2024, TD Cowen has decreased its “an Outperform” rating to a “Market perform” for IMRX. Earlier on March 15, 2024, Jefferies downgraded its rating. Their new recommendation was “a Hold” for IMRX stock which previously was a “a Buy”.
Analyzing IMRX Stock Performance
On last trading session,, Immuneering Corp [NASDAQ: IMRX] rose 52.20% to $2.77. During the last five days, there has been a surge of approximately 30.66%. Over the course of the year, Immuneering Corp shares have jumped approximately 25.91%. Shares of the company reached a 52-week high of $3.80 on 01/07/25 and a 52-week low of $1.10 on 05/12/25.
Support And Resistance Levels for Immuneering Corp (IMRX)
According to the 24-hour chart, there is a support level at 2.23, which, if violated, would cause prices to drop to 1.69. In the upper region, resistance lies at 3.14. The next price resistance is at 3.51. RSI (Relative Strength Index) is 68.04 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Immuneering Corp (IMRX)?
In terms of Immuneering Corp share price expectations, FactSet research, analysts set an average price target of 13 in the next 12 months, up nearly 614.29% from the previous closing price of $1.82. Analysts anticipate Immuneering Corp stock to reach 41 by 2025, with the lowest price target being 3. In spite of this, 3 analysts ranked Immuneering Corp stock as Buy at the end of 2025. On December 01, 2023, Needham assigned a price target of “a Buy” to the stock and initiated coverage with a $20.
